Antares Pharma, Inc.
ATRS
ATRS was delisted on the 23rd of May, 2022.
83 hedge funds and large institutions have $57.2M invested in Antares Pharma, Inc. in 2016 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 30 increasing their positions, 22 reducing their positions, and 16 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 22
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less funds holding
Funds holding: 88 → 83 (-5)
28% less capital invested
Capital invested by funds: $79.4M → $57.2M (-$22.2M)
31% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
+$3.49M |
| 2 |
Morgan Stanley
New York
|
+$2.47M |
| 3 |
AC
Armistice Capital
New York
|
+$2.1M |
| 4 |
Renaissance Technologies
New York
|
+$818K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$412K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$4.82M |
| 2 |
Millennium Management
New York
|
-$2.62M |
| 3 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$1.26M |
| 4 |
KCM
Kingdon Capital Management
New York
|
-$688K |
| 5 |
TI
Turner Investments
Berwyn,
Pennsylvania
|
-$537K |
ATRS Hedge Fund Activity: Q1 2016 in Review
83 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q1 2016, worth a combined $57.2M — down 28% from $79.4M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ATRS and 11 opened new positions — a net loss of 5 holders — while 22 trimmed existing stakes and 30 added.
The largest buyer was Broadfin Capital, adding an estimated $3.49M. The largest seller was Deerfield Management, exiting entirely with an estimated $4.82M sold.
- 83 institutional investors held Antares Pharma, Inc. (ATRS) as of Q1 2016, down from 88 in Q4 2015.
- Funds reported $57.2M of Antares Pharma, Inc. stock for Q1 2016, down 28% quarter-over-quarter.
- 11 funds opened new Antares Pharma, Inc. positions in Q1 2016 and 16 closed out, a net change of -5 holders.
- The largest Antares Pharma, Inc. buyer in Q1 2016 was Broadfin Capital, an estimated $3.49M added.
- The largest Antares Pharma, Inc. seller in Q1 2016 was Deerfield Management, an estimated $4.82M sold.
Based on aggregated 13F filings for Q1 2016.